|  |  |  |
| --- | --- | --- |
| **Version** | **Date** | **Revision** |
| R00 | 3/25/14 | Original issue |
| R01 | 9/8/17 | Check determination on pre-review, clarify non-committee to designated reviewer, remove completion options, clarify text |
| R02 | 8/29/18 | Addition to document and justify omission of consent elements from written scripts |
| R03 | 1/23/19 | Revised to conform with revised Common Rule requirements and recent FDA guidance. |
| R04 | 11/18/19 | Revised to remove screening procedures section, as screening is no longer part of the research per the new common rule. |
| R04 | 12/16/2020 | Annual review, no changes |
| R05 | 10/2021 | Addition to instructions, regarding additional IRB requirements |
| R06 | 12/15/2022 | Addition to instructions, regarding additional IRB requirements |
| R06 | 11/30/23 | Annual review, no changes. |

|  |  |
| --- | --- |
| The purpose of this checklist is to provide support for IRB members or the Designated Reviewer following the WORKSHEET: Criteria for Approval (HRP-314) when research involves the waiver of written documentation of consent. This checklist must be used for all reviews (initial, continuing, modification, review by the convened IRB, and review using the expedited procedure.) In addition to these, the IRB may require additional information/measures to protect human subjects.   * For initial review using the expedited procedure and modifications and continuing reviews where the determinations relevant to this checklist made on the previous review have changed, the Designated Reviewer completes this checklist to document determinations required by the regulations along with protocol specific findings justifying those determinations. The Designated Reviewer attaches this checklist to “Submit Non-Committee Review” activity. The IRB Office retains this checklist in the protocol file. * For initial review using the convened IRB and for modifications and continuing reviews where the determinations relevant to this checklist made on the previous review have changed, the convened IRB completes this checklist to document determinations required by the regulations along with protocol specific findings justifying those determinations and the IRB Office uploads this checklist in the “Submit Committee Review” activity and retains this checklist in the protocol file.   **Use a separate checklist for each waiver determination for a study.** | |
|  | |
| The research must meet one of the following sets of criteria | |
|  | |
| 1. Waiver of Written Documentation of Consent[[1]](#footnote-1) (Check if “Yes”. All must be checked.) | |
|  | The written script of the information to be provided orally (if consent is obtained in person) and all written information to be provided or electronically displayed include all required and appropriate additional elements of consent disclosure in **Section 7: ELEMENTS OF CONSENT DISCLOSURE** in theWORKSHEET: Criteria for Approval (HRP-314)**.** |
|  | The research presents no more than Minimal Risk of harm to subjects. |
|  | The research involves no procedures for which written consent is normally required outside of the research context. |
| Select one of the following: **(One must be checked)**  Written information describing the research **is to be provided** to the subject or the subject’s Legally Authorized Representative (LAR).  Written information describing the research **does not need to be provided** to the subject or the subject’s LAR. | |
|  | |
| 1. Waiver of Written Documentation of Consent[[2]](#footnote-2) (Check if “Yes”. All must be checked) | |
|  | The research is not FDA-regulated. |
|  | The written script of the information to be provided orally and all written information to be provided include all required and appropriate additional elements of consent disclosure in **Section 7: ELEMENTS OF CONSENT DISCLOSURE** in theWORKSHEET: Criteria for Approval (HRP-314)**.** |
|  | The only record linking the subject and the research would be the consent document. |
|  | The principal risk of a signed consent document would be the potential harm resulting from a breach of confidentiality. |
|  | Each subject or LAR will be asked whether the subject wants documentation linking the subject with the research, and the subject’s wishes will govern. |
| Select one of the following: **(One must be checked)**  Written information describing the research **is to be provided** to the subject or the subject’s legally authorized representative.  Written information describing the research **does not need to be provided** to the subject or the subject’s legally authorized representative. | |
|  | |
| 1. Waiver of Written Documentation of Consent[[3]](#footnote-3) (Check if “Yes”. All must be checked) | |
|  | The research is not FDA-regulated. |
|  | The research is subject to the 2018 Rule. |
|  | The written script of the information to be provided orally and all written information to be provided includes all required and appropriate additional elements of consent disclosure in **Section 7: ELEMENTS OF CONSENT DISCLOSURE** in theWORKSHEET: Criteria for Approval (HRP-314)**.** |
|  | The subjects or LAR are members of a distinct cultural group or community in which signing forms is not the norm. |
|  | The research presents no more than Minimal Risk of harm to subjects. |
|  | There is an appropriate alternative mechanism for documenting that informed consent was obtained. |
| Select one of the following: (One must be checked)  Written information describing the research is to be provided to the subject or the subject’s LAR.  Written information describing the research does not need to be provided to the subject or the subject’s LAR. | |
| 1. Waiver of Documentation of the Consent Process – Screening, Recruiting, and Determining Eligibility (Check if “Yes”. All must be checked) | |
|  | The investigator will obtain information through oral or written communication with the prospective subject or legally authorized representative, or |
|  | The investigator will obtain identifiable private information or identifiable biospecimens by accessing records or stored identifiable biospecimens. |
|  | The research is not regulated by the US FDA. |
| 1. Waiver of Documentation of the Consent Process: Distinct Cultural Groups (Check if “Yes”. All must be checked) | |
|  | The research presents no more than minimal risk of harm to subjects. |
|  | The subjects or legally authorized representatives are members of a distinct cultural group or community in which signing consent documents is not the norm. |
|  | There is an appropriate alternative mechanism for documenting that informed consent was obtained |
|  | The oral or written information provided to subjects includes all required and appropriate additional elements of consent disclosure. |
|  | The IRB will determine whether the investigator should provide subjects with a written statement regarding the research. |
|  | The research is not regulated by the US FDA. |

1. 21 CFR §56.109(c)(1) and 45 CFR §46.117(c)(1)(ii) [↑](#footnote-ref-1)
2. 45 CFR §46.117(c)(1)(i) [↑](#footnote-ref-2)
3. 45 CFR §46.117(c)(1)(iii) [↑](#footnote-ref-3)